13 completed, 7 terminated, 3 unknown, 2 recruiting. 25 Phase 2, 11 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 25 | Completed 13, Terminated 7, Unknown 3, Recruiting 2 |
| Phase 1 | 11 | Terminated 6, Completed 4, Unknown 1 |
| Phase 3 | 2 | Recruiting 1, Unknown 1 |
Follow Neoplasm: new trials by email Literature Review of Neoplasm trials Research Report on Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enhancing Successful Return to Work of Employees With Cancer, by Supporting Employers (MiLES Intervention) MiLES - Cancer, Neoplasm | Phase 2 / Phase 3 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 140 | 2023-12-18 | 2024-11-04 |
| Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors SAR444200, Atezolizumab - Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 33 | 2022-09-20 | 2026-01-14 |
| The Role of 5-Aminolevulinic Acid Fluorescence-Guided Surgery in Head and Neck Cancers: a Pilot Trial 5-Aminolevulinic acid Hydrochloride - Neoplasm, Skull Base Neoplasm | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2021-09-14 | 2025-07-28 |
| Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors SAR444881, Pembrolizumab, Cetuximab - Cancer, Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 125 | 2021-04-11 | 2026-09-29 |
| Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment Bevacizumab - Neoplasm, Colorectal Cancer | Phase 2 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 46 | 2020-09-01 | 2020-09-02 |
| Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies Isatuximab SAR650984, Atezolizumab - Neoplasm | Phase 1 / Phase 2 | Terminated | Sanofi | 107 | 2018-08-06 | 2023-07-10 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors BMS-986226, Nivolumab, Ipilimumab - Cancer, Tumors | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 80 | 2017-09-01 | 2023-02-28 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
| A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma Erdafitinib - Neoplasm | Phase 2 | Completed | Janssen Research & Development, LLC | 35 | 2016-07-08 | 2025-04-27 |
| Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy Topical Phenylephrine Solution - Neoplasm, Oral Mucosa | Phase 1 / Phase 2 | Terminated | University of Wisconsin, Madison | 3 | 2015-05-14 | 2019-12-09 |
| A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors ASN002 Dose Escalation, ASN002 RD - Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell | Phase 1 / Phase 2 | Terminated | Asana BioSciences | 51 | 2015-05-01 | 2023-06-07 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| Cancers Treated With Combination of Antrodia Cinnamomea and Chemotherapy AC-Can, placebo - Neoplasm, Functional Gastrointestinal Disorder | Phase 2 / Phase 3 | Unknown | Chang Gung Memorial Hospital | 64 | 2010-06-01 | 2011-02-08 |
| Study of Pegylated Human Recombinant Arginase for Liver Cancer (BCT-100-002) Pegylated Recombinant Human Arginase I - Neoplasm, Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Bio-Cancer Treatment International Limited | 20 | 2010-03-01 | 2012-03-14 |
| Peri-Operative Management of Patients Undergoing Laparoscopic Colorectal Surgery epidural, PCA, Spinal - Neoplasm, Diverticular Disease | Phase 1 / Phase 2 | Unknown | Minimal Access Therapy Training Unit | 99 | 2007-12-01 | 2008-09-05 |
| Study of ADI-PEG 20 in Patients With Advanced Melanoma ADI PEG 20 - Metastatic Melanoma, Skin Cancer | Phase 1 / Phase 2 | Completed | Ludwig Institute for Cancer Research | 31 | 2007-07-01 | 2022-10-25 |
| MK2461 Phase I/II Study in Patients With Advanced Solid Tumors (MK-2461-002 AM1)(COMPLETED) MK2461 - Neoplasm | Phase 1 / Phase 2 | Completed | Merck Sharp & Dohme LLC | 26 | 2007-06-01 | 2015-03-31 |
| PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma PTK787/ZK222584 - Neoplasm | Phase 2 | Completed | Pancreatic Cancer Research Team | 67 | 2005-12-01 | 2012-05-09 |
| Erbitux (Cetuximab) Given Alone to Patients With EGFR-Negative Metastatic Colon or Rectal Cancer That is Refractory to Chemotherapy cetuximab - Colorectal Neoplasms, Metastases | Phase 2 | Completed | Eli Lilly and Company | 87 | 2004-10-01 | 2011-05-25 |
| Extension Program for Bay 43-9006 Nexavar (Sorafenib, BAY43-9006) - Neoplasm, Metastasis | Phase 2 | Completed | Bayer | 9 | 2002-12-01 | 2014-12-23 |
Showing 20 of 25. Sign in to see all of them.
Neoplasms (25) · Neoplasm Metastasis (4) · Melanoma (3) · Colorectal Neoplasms (2) · Acrocephalosyndactylia (1) · Adenocarcinoma (1) · Agnosia (1) · Breast Neoplasms (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Cholangiocarcinoma (1) · Dermatofibrosarcoma (1) · Diverticular Diseases (1) · Esophageal Neoplasms (1) · Fibrosarcoma (1)
Neoplasms by Site (9) · Neoplasms by Histologic Type (8) · Digestive System Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (5) · Digestive System Neoplasms (4) · Gastrointestinal Diseases (4) · Neoplasms, Glandular and Epithelial (4) · Neoplastic Processes (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Carcinoma (3) · Gastrointestinal Neoplasms (3) · Neoplasms, Germ Cell and Embryonal (3) · Neoplasms, Nerve Tissue (3)
Bevacizumab (3) · atezolizumab (3) · Cetuximab (2) · Ipilimumab (2) · Nivolumab (2) · erdafitinib (2) · pembrolizumab (2) · 130-nm albumin-bound paclitaxel (1) · 5H-benzo(4,5)cyclohepta(1,2-b)pyridin-5-one (1) · ADI PEG20 (1) · Afatinib (1) · Albumin-Bound Paclitaxel (1) · Alpelisib (1) · Aminolevulinic Acid (1) · Axitinib (1)
National Cancer Institute (NCI) (3) · Sanofi (3) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Asana BioSciences (1) · Bayer (1) · Bio-Cancer Treatment International Limited (1) · BioNumerik Pharmaceuticals, Inc. (1) · Bristol-Myers Squibb (1) · Celgene (1) · Chang Gung Memorial Hospital (1) · Eli Lilly and Company (1) · Icahn School of Medicine at Mount Sinai (1) · Janssen Research & Development, LLC (1) · Ludwig Institute for Cancer Research (1) · Merck Sharp & Dohme LLC (1)
United States (17) · Canada (7) · China (3) · Netherlands (3) · Spain (3) · Taiwan (3) · United Kingdom (3) · Belgium (2) · Italy (2) · South Korea (2) · Switzerland (2) · Argentina (1) · Czechia (1) · France (1) · Germany (1)
Alfred-Marc Iloreta, MD (1) · Anna Pavlick, DO (1) · E.E. Voest, prof. (1) · Gary Schwartz, MD (1) · Ileana Elias, M.D. (1) · Jedd Wolchok, MD, PhD (1) · Margo L. Hoover-Regan (1) · Mollie Shulan, MD (1) · Niranjan Rao, PhD (1)
PMID 22864522, PMID 27565426, PMID 31401903, PMID 32554315, PMID 33856599, PMID 35086719, PMID 35598186, PMID 36096532, PMID 36870947, PMID 37424386, PMID 38630551, PMID 39138436, PMID 41102780, PMID 41986720
2017 (1), 2018 (1), 2023 (1)